What is PF-07915048 Influenza saRNA used for?

PF-07915048 Influenza saRNA is indicated for Influenza.

Who makes PF-07915048 Influenza saRNA?

PF-07915048 Influenza saRNA is developed by Pfizer.

What development phase is PF-07915048 Influenza saRNA in?

PF-07915048 Influenza saRNA is FDA-approved (marketed).

What is the generic name of PF-07915048 Influenza saRNA?

pf-07915048-influenza-sarna is the generic (nonproprietary) name of PF-07915048 Influenza saRNA.

Last reviewed 2026-04-20 · How we verify

PF-07915048 Influenza saRNA (pf-07915048-influenza-sarna)

Pfizer · FDA-approved active Quality 35/100

PF-07915048 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug has 1 trial and 0 publications. It is a first-in-class drug.

At a glance

Generic name	pf-07915048-influenza-sarna
Sponsor	Pfizer
Drug class	RNA-based therapy
Target	influenza virus
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

Influenza

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Darunavir
Lopinavir
Ritonavir
Saquinavir
Tipranavir
Fosamprenavir
Indinavir
Nelfinavir
Efavirenz
Rilpivirine
Etravirine

Key clinical trials

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07915048 Influenza saRNA CI brief — competitive landscape report
PF-07915048 Influenza saRNA updates RSS · CI watch RSS
Pfizer portfolio CI